Form 4 Tracker
Kalaris Therapeutics, Inc.
KLRS

5 insider filings · Latest: Mar 19, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Oct 22, 2024Oct 23 12:00 AMHagen Brett R
Proposed Sale
486$0.7675$373

View →

Oct 22, 2024Oct 23 12:00 AMMiller Edward
Proposed Sale
766$0.7676$588

View →

Oct 22, 2024Oct 23 12:00 AMSinha Vikas
Proposed Sale
1,882$0.7678$1.4K

View →

Oct 21, 2024Oct 22 12:00 AMSinha Vikas
Proposed Sale
1,546$0.7788$1.2K

View →

Oct 21, 2024Oct 22 12:00 AMHagen Brett R
Proposed Sale
479$0.7787$373

View →

Oct 21, 2024Oct 22 12:00 AMMiller Edward
Proposed Sale
635$0.7795$495

View →

Oct 21, 2024Oct 22 12:00 AMBrainard Diana
Proposed Sale
9,752$0.7789$7.6K

View →

Oct 3, 2024Oct 4 12:00 AMMiller Edward
Proposed Sale
377$0.8143$307

View →

Oct 3, 2024Oct 4 12:00 AMHagen Brett R
Proposed Sale
301$0.814$245

View →

Oct 3, 2024Oct 4 12:00 AMBrainard Diana
Proposed Sale
1,493$0.8145$1.2K

View →

Oct 3, 2024Oct 4 12:00 AMSinha Vikas
Proposed Sale
940$0.8149$766

View →

Aug 20, 2024Aug 21 3:14 PMBrainard Diana
Proposed Sale
5,390$0.7414$4.0K

View →

← Previous

Page 2 of 2

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Mar 19, 2026Mar 23 8:05 PMBrett R HagenChief Accounting Officer
Grant/Award
60,800$6.8160,800(D)

View →

Mar 19, 2026Mar 20 8:05 PMAndrew OxtobyDirector, President and Chief Executive Officer
Grant/Award
222,000$6.81222,000(D)

View →

Mar 19, 2026Mar 20 8:05 PMMatthew GallChief Financial Officer
Grant/Award
95,000$6.8195,000(D)

View →

Mar 19, 2026Mar 20 8:05 PMMatthew FeinsodChief Medical Officer
Grant/Award
135,000$6.81135,000(D)

View →